Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hiesse, C.
Right arrow Articles by Charpentier, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hiesse, C.
Right arrow Articles by Charpentier, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1992) 7: 944-951
© 1992 European Renal Association-European Dialysis and Transplant Association

research-article

Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation

C. Hiesse1,, F. Kriaa1, P. Rousseau1, H. Farahmand2, A. Bismuth2, D. Fries1 and B. Charpentier1

1Service de Néphrologie, Hôpital de Bicetre, Le Kremlin-Bicetre Université Paris-Sud, France 2Centre de Transfusioni Sanguine, Hôpital Paul Brousse, Villejuif; Université Paris-Sud, France

Correspondence and offprint requests to: Correspondence and offprint requests to: C. Hiesse, MD, Servicede Nephrologie, Hôpital de Bicètre, 78, rue du Général Lederc, 94275 Le Kremlin-bicêtre CEDEX France.

Fifteen end-stage renal disease patients with high titres of panel reactive (PRA) antibodies were treated with immunoadsorption (IA) on sepharosebound protein A columns in order to remove antiHLA antibodies and facilitate transplantation. Infectious complications were not observed after IA and transplantation, and the procedure was well tolerated. In spite of the use of adjunctive immunosuppressive treatment with cyclophosphamide and prednisolone, this method produced only variable effects in lowering panel reaction antibodies, and was hampered by high de novo resynthesis of anti-HLA antibodies. Patients whose pre-IA antibody titre was greater double equals1:64 clearly did not benefit from the procedure, but other immunological criteria were not predictive of efficacy. Twelvepatients were transplanted on the basis of a negativecross-match with current serum, historical sera being retrospectively tested. Surprisingly, seven patients received a well-matched graft with both pre- and post-IA negative cross-matching. Graft survival was 86% in this group. Conversely, in the group of fivetransplants which were performed in recipients having a positive historical cross-match with the donor, graft survival was only 40%. One patient died with afunctional graft, and two grafts failed due to hyperacute humoral rejection. Humoral rejection in a third patient was successfully treated by a second IA course and administration of polyclonal IgG. We conclude that IA is a safe procedure for managing hyperimmunized transplant candidates. However, its efficacy remains variable, and a better definition of patients who should benefit from IA needs to be found.

Keywords: immunoadsorption; HLA antibody; kidney transplantation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
M. Karpinski, D. Rush, J. Jeffery, M. Exner, H. Regele, S. Dancea, D. Pochinco, P. Birk, and P. Nickerson
Flow Cytometric Crossmatching in Primary Renal Transplant Recipients with a Negative Anti-Human Globulin Enhanced Cytotoxicity Crossmatch
J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2807 - 2814.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.